Clinical trial
First Line Therapy for Patients With Metastatic Breast Cancer
NCT00456846 · Celgene, Industry · Terminated
Key facts
| NCT number | NCT00456846 |
|---|---|
| Title | First Line Therapy for Patients With Metastatic Breast Cancer |
| Official title | An Open-Label, Phase II Study of Weekly ABI-007 as First Line Therapy for Patients With Metastatic Breast Cancer |
| Lead sponsor | Celgene, Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Metastatic Breast Cancer |
| Intervention type | Drug |
| Interventions | ABI-007 |
| Enrollment | 123 |
| Start date | Feb 1, 2008 |
| Primary completion | Dec 11, 2012 |
| Completion | May 31, 2013 |
| First posted | Apr 5, 2007 |
| Last update posted | Nov 22, 2019 |
| Countries | Canada |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: